ReNeuron raises £33.2m

The £100m Wales Life Sciences Investment Fund, managed by Arthurian Life Sciences, committed £5m in equity. 

Co-investment was provided by Invesco and Abingworth Partners, alongside other institutional investors including hedge funds. The Welsh government provided a £7.8m commitment in the form of non-dilutive grants. 

The funding packages will enable the firm to grow its stem cell R&D programme, to relocate to Wales and to accelerate clinical trials. 

Company
Founded in 1997, ReNeuron is a clinical-stage stem cell company. Its primary objective is to develop novel stem cell therapies targeting unmet medical needs. The firm's ordinary shares are listed on AIM. 

The firm's leading development is a stem cell therapy for the treatment of patients disabled by a stroke. The therapy is currently in clinical development. Further therapies targeting conditions including critical limb ischaemia, a side-effect of diabetes, and diseases of the retina are also in development. 

People
Chris Evans, founder of Arthurian Life Sciences, will join the ReNeuron board as part of the transaction. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Expansion
• United Kingdom